四水合二喹法索钠：一种新型干眼症治疗药物。
Diquafosol tetrasodium: a novel dry eye therapy.
作者信息
Nichols Kelly K, Yerxa Ben, Kellerman Donald J
机构信息
The Ohio State University, College of Optometry, Columbus, OH, USA.
出版信息
Expert Opin Investig Drugs. 2004 Jan;13(1):47-54. doi: 10.1517/13543784.13.1.47.
The ophthalmic formulation of diquafosol tetrasodium (INS365), a P2Y2 receptor agonist, is targeted to treat dry eye disease through rehydration of the ocular surface. Existing pharmacological therapies for dry eye disease are limited, therefore, approval of this medication is anticipated. This review summarises key findings during development and in clinical trials including clinical effectiveness and safety. The relevance of P2Y2 receptor technology to dry eye disease and the disease process is discussed.
二喹法索四钠（INS365）是一种P2Y2受体激动剂，其眼科制剂旨在通过眼表补水来治疗干眼症。现有的干眼症药物疗法有限，因此，预计该药物将获批。本综述总结了其研发过程和临床试验中的关键发现，包括临床有效性和安全性。还讨论了P2Y2受体技术与干眼症及疾病进程的相关性。
Zotero 插件